Our patent-pending technology enables us to stratify risk and prioritize patients for trials via actual electronic health record (EHR) review across providers and allows us to extract data and create algorithms that prequalify and identify ideal patients for trials. This unique, integrated approach allows us to learn from the data, make inferences, and continually improve our algorithms over time – leading to more ideal patient identification for each succeeding trial.
How It Works
- Prior to a visit with their healthcare provider, a patient’s medical history is reviewed by ObjectiveScreen’s advanced AI algorithms to determine their risk for having an undiagnosed condition like nonalcoholic fatty liver disease (NAFLD).
- If a high-risk level is detected, a notification is sent to their healthcare provider to let them know that the disease may be present and that the patient may be a good candidate for novel treatments that are available through clinical trials.
- When the patient arrives for their appointment, their healthcare provider then has an opportunity to use the risk stratification provided by ObjectiveScreen to offer clinical trial research as a treatment option.
- If the patient expresses interest in research as a treatment option, they are directed to their provider for further guidance and information on research opportunities.